Abstract:
The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
Abstract:
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
Abstract:
The present invention relates to aminotriazole compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.
Abstract:
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
Abstract:
The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
Abstract:
Compounds represented by formula (I) or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B', X, Y, R1, R1 ', R2, R2', R3, R3', R5, R5', R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.
Abstract:
SE REFIERE A COMPUESTOS DE AMINOTRIAZOLES DE FORMULA I, EN DONDE R1 ES H o ALQUILO C1-C6; R2 ES (T)nR, (T)nAr1 o (T)nCi1; T ES UNA CADENA OPCIONALMENTE SUSTITUIDA DE ALQUILIDENO C1-C4; n ES 0 o 1; Ar1 ES UN GRUPO ARILO SELECCIONADO ENTRE UN MONOCICLO DE 5-6 MIEMBROS o UN ANILLO BICICLICO DE 8-10 MIEMBROS CON 0-5 HETEROATOMOS SELECCIONADOS DE N, O o S; Ci1ES UN ANILLO MONOCICLICO DE 3-7 MIEMBROS CON 0-3 HETEROATOMOS SELECCIONADOS DE N, O o S o UN ANILLO BICICLICO DE 8-10 MIEMBROS CON 0-5 HETEROATOMOS SELECCIONADOS DE N, O o S; o R1 Y R2 TOMADOS JUNTOS CON EL N FORMAN UN ANILLO DE HETEROARILO DE 5-8 MIEMBROS o UN ANILLO HETEROARILO DE 5-8 MIEMBROS CON 1-3 HETEROATOMOS SELECCIONADOS DE N, O o S; R3 ES (L)mR; (L)mCi2, ENTRE OTROS; L ES UNA CADENA DE ALQUILIDENO C1-C4 OPCIONALMENTE SUSTITUIDA; m ES 0 o 1; Ci2 ES UN ANILLO MONOCICLICO DE 3-7 MIEMBROS CON 0-3 HETEROATOMOS SELECCIONADOS DE N, O o S o UN ANILLO BICICLICO DE 8-10 MIEMBROS CON 0-5 HETEROATOMOS SELECCIONADOS DE N, O o S; o R2 Y R3 TOMADOS EN CONJUNTO FORMAN UN ANILLO COMPLETAMENTE NO SATURADO QUE CON 0-3 HETEROATOMOS SELECCIONADOS DE N, O o S, UN ANILLO DE 8-10 MIEMBROS CON 0-3 HETEROATOMOS SELECCIONADOS DE N, O o S, ENTRE OTROS; R ES H o UN GRUPO ALIFATICO C1-C6 OPCIONALMENTE SUSTITUIDO. UN COMPUESTO PREFERIDO ES 1-{4-[6-(3-FENILAMINO-[1,4]TRIAZOL-1-IL]-[1,4]DIAZEPAM-1-IL}-ETANONA. TAMBIEN SE REFIERE A UNA COMPOSICON FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE QUINASAS
Abstract:
Los compuestos representados por la fórmula (I): (ver fórmula (I)) o sales y solvatos farmacéuticamente aceptables de los mismos, en donde A, B, B', X, Y, R1, R1', R2, R2', R3, R3', R5, R5´, R6, m, n o p son como se define en la presente, son útiles para el tratamiento de infecciones virales por flaviviridae.